Cargando…

Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China

OBJECTIVE: Refractory rifampicin-resistant/multidrug resistant/extensively-drug resistant tuberculosis (RR/MDR/XDR-TB) were defined as patients infected with Mycobacterium tuberculosis (MTB) resistant to rifampicin(RR-TB), or at least resistant to rifampicin and isoniazid (MDR-TB) or added resistant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Shao-Jun, Yang, Yan, Sun, Wen-Wen, Zhang, Zhong-Shun, Xiao, He-Ping, Li, Yu-Ping, Zhang, Zhe-Min, Fan, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422092/ https://www.ncbi.nlm.nih.gov/pubmed/36038829 http://dx.doi.org/10.1186/s12879-022-07693-9

Ejemplares similares

Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy
por: Codecasa, Luigi R., et al.
Publicado: (2017)

MDR & XDR Tuberculosis
por: Kumar, Prahlad
Publicado: (2017)

Safety and effectiveness of all-oral and injectable-containing, bedaquiline-based long treatment regimen for pre-XDR tuberculosis in Vietnam
por: Nguyen, Thi Mai Phuong, et al.
Publicado: (2022)

Interim Effectiveness and Safety Comparison of Bedaquiline-Containing Regimens for Treatment of Diabetic Versus Non-Diabetic MDR/XDR-TB Patients in China: A Multicenter Retrospective Cohort Study
por: Shi, Li, et al.
Publicado: (2021)

Transmission of MDR and XDR Tuberculosis in Shanghai, China
por: Zhao, Ming, et al.
Publicado: (2009)

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
por: Khan, Uzma, et al.
Publicado: (2019)

The Burden of MDR/XDR Tuberculosis in Coastal Plains Population of China
por: Yang, Xiujun, et al.
Publicado: (2015)

First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB
por: Lewis, Joseph M., et al.
Publicado: (2016)

Linezolid-Associated Neuropathy in Patients with MDR/XDR Tuberculosis in Shenzhen, China
por: Zhang, Peize, et al.
Publicado: (2022)

Activity of Semi-Synthetic Mulinanes against MDR, Pre-XDR, and XDR Strains of Mycobacterium tuberculosis
por: Martínez-González, María Alejandrina, et al.
Publicado: (2021)

The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks
por: Sirgel, Frederick A., et al.
Publicado: (2013)

Analysing non-synonymous mutations in XDR and MDR tuberculosis drugs
por: Surana, Pallavi, et al.
Publicado: (2019)

Rapid diagnosis of MDR and XDR tuberculosis with the MeltPro TB assay in China
por: Pang, Yu, et al.
Publicado: (2016)

Correction: The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks
por: Sirgel, Frederick A., et al.
Publicado: (2015)

Prevalence of pre-extensively drug-resistant tuberculosis (Pre XDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) among extra pulmonary (EP) multidrug resistant tuberculosis (MDR-TB) at a tertiary care center in Mumbai in pre Bedaquiline (BDQ) era
por: Utpat, Ketaki V., et al.
Publicado: (2023)

Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety
por: Gao, Jing-Tao, et al.
Publicado: (2021)

Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis
por: Hatami, Hossein, et al.
Publicado: (2022)

Effectiveness and Nephrotoxicity of Intravenous Polymyxin B in Chinese Patients With MDR and XDR Nosocomial Pneumonia
por: Zeng, Huihui, et al.
Publicado: (2021)

Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis Strains
por: Hameed, H. M. Adnan, et al.
Publicado: (2018)

Association of anti-tuberculosis drug concentrations in hair and treatment outcomes in MDR- and XDR-TB
por: Metcalfe, John, et al.
Publicado: (2019)

Long-term impact of the adoption of bedaquiline-containing regimens on the burden of drug-resistant tuberculosis in China
por: Agnarson, Abela Mpobela, et al.
Publicado: (2020)

Bedaquiline (BDQ) resistance in an adolescent with multidrug-resistant tuberculosis (MDR-TB): An alarm for pediatricians
por: Cesilia, Citra, et al.
Publicado: (2023)

Global trends in the incidence rates of MDR and XDR tuberculosis: Findings from the global burden of disease study 2019
por: Bu, Qingting, et al.
Publicado: (2023)

MDR and XDR typhoid fever-a threat for the current decade?
por: Pustake, Manas, et al.
Publicado: (2021)

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis
por: Xu, Jian, et al.
Publicado: (2019)

1884. Clinical Outcomes Among Patients with Drug-Resistant Tuberculosis Receiving Bedaquiline or Delamanid Containing Regimens
por: Kempker, Russell R, et al.
Publicado: (2019)

Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort( )
por: Hewison, Catherine, et al.
Publicado: (2022)

Classification of Mycobacterium tuberculosis DR, MDR,XDR Isolates and Identification of Signature MutationPattern of Drug Resistance
por: Prasanna, Akshatha, et al.
Publicado: (2019)

Prolonged use of bedaquiline in the treatment for MDR-TB in a child
por: Gubkina, Marina F., et al.
Publicado: (2021)

Effective use of telemedicine in Mumbai with a cohort of extensively drug-resistant “XDR” tuberculosis patients on bedaquiline during COVID-19 pandemic
por: Udwadia, Zarir F., et al.
Publicado: (2021)

Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa
por: Mohr-Holland, Erika, et al.
Publicado: (2020)

Age of Antibiotic Resistance in MDR/XDR Clinical Pathogen of Pseudomonas aeruginosa
por: Kothari, Ashish, et al.
Publicado: (2023)

Correction to: Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
Publicado: (2023)

Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates
por: Kaniga, Koné, et al.
Publicado: (2022)

Factors associated with treatment outcome of MDR/RR-TB patients treated with shorter injectable based regimen in West Java Indonesia
por: Soeroto, Arto Yuwono, et al.
Publicado: (2022)

Risk Factors for MDR and XDR-TB in a Tertiary Referral Hospital in India
por: Balaji, V., et al.
Publicado: (2010)

The Role of Adjunctive Therapies in Septic Shock by Gram Negative MDR/XDR Infections
por: Busani, Stefano, et al.
Publicado: (2017)

Does optimized adherence support improve treatment outcomes in RR / MDR-TB patients on 18–20 months regimen in Tbilisi, Georgia?
por: Jomidava, Tinatin, et al.
Publicado: (2021)

The Anti-Mycobacterial Activity Of Ag, ZnO, And Ag- ZnO Nanoparticles Against MDR- And XDR-Mycobacterium tuberculosis
por: Heidary, Mohsen, et al.
Publicado: (2019)

Diagnosis and Treatment Pathway of MDR/RR-TB in Taizhou, Zhejiang Province, China
por: Lu, Jingting, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sprrq45pgf8kpllcgb4kiv61r3